All Officials
Select methods...
Lobbying Records (Page 1 of 16)
Politician(s) lobbied: John Newham (Assistant Secretary), Department of Enterprise, Trade and Employment; Muiris O’Connor (Assistant Secretary), Department of Health; John Shaw (Assistant Secretary), Department of the Taoiseach
Intent: Ireland to consider and support proposals for improving access to medicines in smaller EU markets from the European Association, EFPIA, and to support the position that such access can be improved without cutting Regulatory Data Protection IP rights.
Methods: Email
Details & Methods:
| Method | Description |
|---|---|
| — | Proposed revision of EU General Pharmaceutical Legislation and Irish Government position on access to medicines in EU smaller countries/markets and intellectual property rights. |
Politician(s) lobbied: John Newham (Assistant Secretary), Department of Enterprise, Trade and Employment
Intent: (i) Consistent with the Programme for Government, Ireland to support maintenance of status quo 8 years of Regulatory Data Protection in EU legislation. (ii) Government/Department of Enterprise to have a stakeholder involvement in developing the Irish Life Sciences Strategy.
Methods: Informal communication
Details & Methods:
| Method | Description |
|---|---|
| — | (i) Proposed revision of EU General Pharmaceutical Legislation and Irish Government position on intellectual property rights. (ii) Proposed Life Sciences Strategy. |
Politician(s) lobbied: Micheál Martin (Taoiseach), Dáil Éireann, the Oireachtas
Intent: (i) To support competitiveness of the pharmaceutical industry in Europe & not dilute or reduce RDP; (ii) Consider adopting IPHA proposal to address delays in the reimbursement of medicines; (iii) For a holistic approach to a life sciences strategy incorporating bench to bedside initiatives; (iv) Take account of importance of the pharmaceutical industry in competitiveness of EU; (v) To understand the impact of tariffs on pharmaceutical industry & for no reciprocal tariffs to be imposed from EU.
Methods: Email
Details & Methods:
| Method | Description |
|---|---|
| — | (i) Proposed revision of EU General Pharmaceutical Legislation and Irish Government position on intellectual Property rights; (ii) Issues concerning the timely reimbursement of medicines in Ireland; (iii) Industry position on a National Life Sciences Strategy; (iv) EU and Irish Competitiveness and the pharmaceutical industry. (v) The potential impact of tariffs on medicines. |
Politician(s) lobbied: Micheál Martin (Taoiseach), Dáil Éireann, the Oireachtas
Intent: (i) To support competitiveness of the pharmaceutical industry in Europe & not dilute or reduce RDP; (ii) Consider adopting IPHA proposal to address delays in the reimbursement of medicines; (iii) For a holistic approach to a life sciences strategy incorporating bench to bedside initiatives; (iv) Take account of importance of the pharmaceutical industry in competitiveness of EU; (v) To understand the impact of tariffs on pharmaceutical industry & for no reciprocal tariffs to be imposed from EU.
Methods: Email
Details & Methods:
| Method | Description |
|---|---|
| — | (i) Proposed revision of EU General Pharmaceutical Legislation and Irish Government position on intellectual Property rights; (ii) Issues concerning the timely reimbursement of medicines in Ireland; (iii) Industry position on a National Life Sciences Strategy; (iv) EU and Irish Competitiveness and the pharmaceutical industry. (v) The potential impact of tariffs on medicines. |
Politician(s) lobbied: Simon Harris (Tánaiste and Minister), Department of Foreign Affairs; Peter Burke (Minister), Department of Enterprise, Trade and Employment; Deirdre Gillane (Chief of Staff), Department of the Taoiseach; John Callinan (Secretary General), Department of the Taoiseach
Intent: (i) To support the competitiveness of the pharmaceutical industry in Europe and not therefore dilute or reduce RDP. (ii) To adopt a holistic approach to a life sciences strategy incorporating bench to bedside initiatives. (iii) To take account of pharmaceutical industry in competitiveness of EU. (iv) To understand the impact on the industry of tariffs on pharmaceutical, and for no reciprocal tariffs to be imposed from the EU.
Methods: Email
Details & Methods:
| Method | Description |
|---|---|
| — | (i) Proposed revision of EU General Pharmaceutical Legislation and Irish Government position on intellectual Property rights; (ii) Industry position on a National Life Sciences Strategy; (iii) EU and Irish Competitiveness and the pharmaceutical industry; (iv) The potential impact of tariffs on medicines. |
Politician(s) lobbied: Simon Harris (Tánaiste and Minister), Department of Foreign Affairs; Peter Burke (Minister), Department of Enterprise, Trade and Employment; Deirdre Gillane (Chief of Staff), Department of the Taoiseach; John Callinan (Secretary General), Department of the Taoiseach
Intent: (i) To support the competitiveness of the pharmaceutical industry in Europe and not therefore dilute or reduce RDP. (ii) To adopt a holistic approach to a life sciences strategy incorporating bench to bedside initiatives. (iii) To take account of pharmaceutical industry in competitiveness of EU. (iv) To understand the impact on the industry of tariffs on pharmaceutical, and for no reciprocal tariffs to be imposed from the EU.
Methods: Email
Details & Methods:
| Method | Description |
|---|---|
| — | (i) Proposed revision of EU General Pharmaceutical Legislation and Irish Government position on intellectual Property rights; (ii) Industry position on a National Life Sciences Strategy; (iii) EU and Irish Competitiveness and the pharmaceutical industry; (iv) The potential impact of tariffs on medicines. |
Politician(s) lobbied: Stephen Foley (Special Adviser), Department of Health; Peter Burke (Minister), Department of Enterprise, Trade and Employment
Intent: (i) To support the competitiveness of the pharmaceutical industry in Europe and not therefore dilute or reduce RPD; (ii) Ireland to take a position to maintain Regulatory Data Protection at status quo, 8 years.
Methods: Informal communication
Details & Methods:
| Method | Description |
|---|---|
| — | (i) Proposed revisions of EU General Pharmaceutical Legislation and (ii) Irish Government Position on intellectual property rights. |
Politician(s) lobbied: Stephen Foley (Special Adviser), Department of Health; Peter Burke (Minister), Department of Enterprise, Trade and Employment
Intent: (i) To support the competitiveness of the pharmaceutical industry in Europe and not therefore dilute or reduce RPD; (ii) Ireland to take a position to maintain Regulatory Data Protection at status quo, 8 years.
Methods: Informal communication
Details & Methods:
| Method | Description |
|---|---|
| — | (i) Proposed revisions of EU General Pharmaceutical Legislation and (ii) Irish Government Position on intellectual property rights. |
Politician(s) lobbied: Jennifer Carroll MacNeill (Minister), Department of Health; Stephen Foley (Special Adviser), Department of Health; Marie Sherlock (TD), Dáil Éireann, the Oireachtas; David Cullinane (TD), Dáil Éireann, the Oireachtas; Duncan Smith (TD), Dáil Éireann, the Oireachtas; John Newham (Assistant Secretary), Department of Enterprise, Trade and Employment; Niall Redmond (Assistant Secretary), Department of Health; Muiris O’Connor (Assistant Secretary), Department of Health; Bernard Gloster (Chief Executive Officer), Health Service Executive; Pat Healy (National Director for Service and Schemes), Health Service Executive; John Callinan (Secretary General), Department of the Taoiseach; Máirín Ryan (Deputy Chief Executive and Director of Health Technology Assessment), Health Information and Quality Authority
Intent: To take account of and consider adopting IPHA proposals to address delays in the reimbursement of medicines.
Methods: Meeting, Email
Details & Methods:
| Method | Description |
|---|---|
| — | Issues concerning the timely reimbursement of medicines in Ireland. |
Politician(s) lobbied: Jennifer Carroll MacNeill (Minister), Department of Health
Intent: (i) To support competitiveness of the pharmaceutical industry in Europe and not therefore dilute or reduce RDP. (ii) To take account of and consider adopting IPHA proposal to address delays in the reimbursement of medicines. (iii) For a holistic approach to a life sciences strategy incorporating bench to bedside initiatives. (iv) To see an increase in the number of clinical trials undertaken in Ireland.
Methods: Email
Details & Methods:
| Method | Description |
|---|---|
| — | (i) Proposed revision of EU General Pharmaceutical Legislation and Irish Government position on intellectual property rights. (ii) Issues concerning the timely reimbursement of medicines in Ireland. (iii) Industry position on a National Life Sciences Strategy. (iv) Number of Clinical Trials in Ireland. |
…